Fresenius Medical Care AG
XMUN:FME

Watchlist Manager
Fresenius Medical Care AG Logo
Fresenius Medical Care AG
XMUN:FME
Watchlist
Price: 42.43 EUR 0.93%
Market Cap: 24.9B EUR
Have any thoughts about
Fresenius Medical Care AG?
Write Note

Fresenius Medical Care AG
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Fresenius Medical Care AG
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Fresenius Medical Care AG
XMUN:FME
Other Receivables
€37.4m
CAGR 3-Years
-30%
CAGR 5-Years
-13%
CAGR 10-Years
-13%
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Other Receivables
€37.4m
CAGR 3-Years
-30%
CAGR 5-Years
-13%
CAGR 10-Years
-13%
Fresenius SE & Co KGaA
XETRA:FRE
Other Receivables
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vita 34 AG
XETRA:V3V
Other Receivables
€129k
CAGR 3-Years
-62%
CAGR 5-Years
-37%
CAGR 10-Years
-24%
E
Euroeyes International Eye Clinic Ltd
HKEX:1846
Other Receivables
HK$18.9m
CAGR 3-Years
-19%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Synlab AG
XETRA:SYAB
Other Receivables
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Fresenius Medical Care AG
Glance View

Market Cap
24.9B EUR
Industry
Health Care

Fresenius Medical Care AG is a global leader in providing products and services for individuals undergoing dialysis as a result of chronic kidney failure. Founded in 1996 and headquartered in Bad Homburg, Germany, the company specializes in the development and manufacture of high-quality dialysis equipment and supplies, including dialysis machines and filters. With a network that spans over 150 countries, Fresenius operates numerous dialysis clinics, delivering essential care to a large and growing patient population. Its commitment to innovation and quality care positions it well within the healthcare sector, making it a compelling option for investors seeking exposure in the medical technology domain. As the prevalence of kidney disease rises, driven by factors such as aging populations and increasing diabetes cases, Fresenius Medical Care is poised to capitalize on this expanding marketplace. The company's robust pipeline of therapeutic solutions and its focus on integrating healthcare technologies demonstrate a proactive approach to enhancing patient outcomes. Additionally, Fresenius benefits from a diversified business model that includes both product manufacturing and direct patient care services, which provides resilience against market fluctuations. Investors looking for a company with a strong balance sheet, consistent revenue growth, and a mission-driven approach to healthcare will find Fresenius Medical Care AG to be an attractive choice in their portfolio.

FME Intrinsic Value
49.49 EUR
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Fresenius Medical Care AG's Other Receivables?
Other Receivables
37.4m EUR

Based on the financial report for Jun 30, 2024, Fresenius Medical Care AG's Other Receivables amounts to 37.4m EUR.

What is Fresenius Medical Care AG's Other Receivables growth rate?
Other Receivables CAGR 10Y
-13%

Over the last year, the Other Receivables growth was -57%. The average annual Other Receivables growth rates for Fresenius Medical Care AG have been -30% over the past three years , -13% over the past five years , and -13% over the past ten years .

Back to Top